This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Snap warns of continued regulatory risk from US 'My AI' chatbot probe

By Mike Swift ( August 7, 2025, 22:44 GMT | Insight) -- Snap disclosed in a securities filing this week that its My AI chatbot remains under the scrutiny of US regulators over youth safety issues. A complaint, referred by the US Federal Trade Commission to the US Department of Justice in January, alleged youth safety concerns with Snap's chatbot, which has also been scrutinized by the Information Commissioner's Office in the UK. Snap says the FTC relied on inaccurate and unproven claims — with potential First Amendment implications — but the social media company said it has continued to add safety and privacy protections to My AI as it works with regulators. Snap said this week its My AI chatbot remains under scrutiny from US enforcers over youth safety concerns, even as the company said it continues to work with agencies to bolster safety while also pushing back on the accuracy and fairness of the complaint....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections